Developmental Funds

项目摘要：发展基金 2012年就任西尔维斯特综合癌症中心(Sylvester)主任后不久， 医学博士斯蒂芬·D·尼默发起了一项中心范围的努力，以确保所有与癌症相关的投资都是 策略性地制造。尼默的第一个目标是系统地建立所需的研究基础设施，将 个人和研究人员团体，建立科学家团队，为中心创建研究项目， 并增加社区参与和外展活动，以更好地了解 西尔维斯特集水区的需求。2013年，西尔维斯特领导层启动了正式的战略规划 这一进程产生了2014-2018年战略计划。这项计划优先解决西尔维斯特的需求 成员，包括需要更好的共享资源(SR)、更可靠的临床支持 试验和转化科学，以及对杰出的癌症研究提供更多的财政支持。自2014年以来，共有 570万美元已通过同行审查的校内资助计划授予，其中包括9个奖项 鼓励癌症研究新领域的机制，过渡性研究人员的拨款，支持青少年 并促进符合西尔维斯特公司战略目标的创新临床试验，并促进协作 团队科学。投资回报，根据直接支持的结果计算 研究项目，已获得2520万美元的新拨款，22本出版物(其中%是合作的)， 新的研究工具，以及三项申请，其中一项专利获得批准。满足三项研究的需要 除了这些项目，西尔维斯特还投资了1400万美元开发流式细胞术、肿瘤基因组学、 生物统计学和生物信息学，以及行为和基于社区的研究共享资源。七十 %的Sylvester成员使用这些共享资源提供的服务。此外，西尔维斯特还拥有 自2016年以来，在三个高度翻译的开发共享资源上投资了290万美元：Biospecimen，癌症 建模和分子治疗共享资源，CCSG发展基金支持 已请求。

PROJECT SUMMARY: DEVELOPMENTAL FUNDS Shortly after assuming the Directorship of Sylvester Comprehensive Cancer Center (Sylvester) in 2012, Stephen D. Nimer, MD, initiated a center-wide effort to ensure that all cancer-relevant investments are strategically made. Nimer’s first goals were to systematically build needed research infrastructure, connect individuals and groups of investigators, build teams of scientists to create research programs for the center, and increase community engagement and outreach activities to gain a greater understanding of the diverse needs in Sylvester’s catchment area. In 2013, Sylvester leadership initiated a formal strategic planning process, resulting in the 2014-2018 Strategic Plan. This plan prioritized addressing the needs of Sylvester members, including the need for better shared resources (SRs), more reliable support for conducting clinical trials and translational science, and more financial support of outstanding cancer research. Since 2014, a total of $5.7M has been awarded via the peer-reviewed Intramural Funding Program, which includes nine award mechanisms to encourage new areas of cancer research, bridge investigator’s grant funding, support junior faculty, and promote innovative clinical trials that match Sylvester’s strategic goals and promote collaborative team science. The return on investment, calculated based on results stemming from the direct support of research projects, has been $25.2M in new grant funding, 22 publications (of which 64% are collaborative), new research tools, and three applications with one patent approved. To fulfill the needs of the three research programs, Sylvester has also invested $14M in the development of the Flow Cytometry, Onco-Genomics, Biostatistics and Bioinformatics, and Behavioral and Community-Based Research Shared Resources. Seventy percent of Sylvester members utilize services these shared resources provide. Additionally, Sylvester has invested $2.9M since 2016 in three highly translational developing shared resources: the Biospecimen, Cancer Modeling, and Molecular Therapeutics Shared Resources, for which CCSG Developmental Funds support is requested.